Navigation Links
Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
Date:7/7/2009

THE WOODLANDS, Texas, July 7 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has initiated a Phase 2 clinical trial of LX1032, the company's oral drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome. LX1032 is designed to reduce serotonin production in patients with metastatic carcinoid tumors. Elevated levels of serotonin contribute to the gastrointestinal and possibly other symptoms experienced by these patients.

In addition to LX1032, Lexicon has three other drug candidates progressing through various stages of clinical development, including LX1031 for irritable bowel syndrome, LX2931 for rheumatoid arthritis, and LX4211 for diabetes. For more information about Lexicon's clinical development programs, please visit www.lexpharma.com.

"This is an important study, designed to evaluate LX1032's effect on the gastrointestinal symptoms experienced by patients with carcinoid syndrome who have become refractory to current treatment options," said Philip M. Brown, M.D., J.D., senior vice president of clinical development at Lexicon. "We are encouraged by the clinical results obtained to date in which LX1032 demonstrated potent reductions in serotonin production in healthy volunteers."

The Phase 2 clinical trial is designed as a four-week, randomi
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
2. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
3. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
4. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
5. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
6. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
7. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
8. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
9. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
10. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
11. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Diagenode, Inc., a leading global ... and complete solutions for epigenetics research, recently launched ... the need for manual processing. The new ChIPettor ... of histones or transcription factors and a semi-automated ...
(Date:1/22/2015)... N.J. , Jan. 22, 2015  Derma Sciences, ... regeneration company focused on advanced wound care, announces ... placental tissues, have been added to the Premier, ... increases the opportunity for the AMNIOEXCEL® and AMNIOMATRIX® ...
(Date:12/24/2014)... Dec. 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and cryopreservation ... for cells and tissues  ("BioLife" or the "Company"), today announced ... on May 4, 2015 (the "Annual Meeting"). Because ...
(Date:12/24/2014)... 2014 On Friday, December 19, 2014, ... and Continuing Resolution Appropriations Act of 2015, which for ... receive funding through the Congressionally Directed Medical Research Programs ... Hydrocephalus Association (HA), working in conjunction with its allies ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... Airlines CEO Larry Kellner, and the Greater Houston Partnership,s ... 23 TechConnect World today announced an all-star cast ... World trio of conferences -- which includes the ... at the George R. Brown Convention Center in Houston, ...
... SEQUENOM, Inc. (Nasdaq: SQNM ), today ... market close on Thursday, April 30, 2009. The company will ... Pacific Time (4:30 pm Eastern Time) on the same day., ... (866) 844-2998, International callers: 1 (706) 679-9912, , ...
... Insmed Inc. (Nasdaq CM: INSM ), ... a conference call on Wednesday, May 13th at 8:30 ... first quarter 2009. Insmed intends to issue its ... on May 13th.To participate in the live conference call, ...
Cached Biology Technology:TechConnect World Conference Showcases Houston Leaders May 3-7, at the George R. Brown Convention Center 2TechConnect World Conference Showcases Houston Leaders May 3-7, at the George R. Brown Convention Center 3SEQUENOM to Hold First Quarter 2009 Financial Results Conference Call on April 30 2Insmed to Host First Quarter 2009 Conference Call 2
(Date:1/22/2015)... man-made form of insulin delivered by nasal spray may ... with mild cognitive impairment and Alzheimer,s disease dementia, according ... Forest Baptist Medical Center. The study,s subjects ... (MCI) or mild to moderate Alzheimer,s dementia (AD). Those ...
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... sectors including technology and tech stocks, releases video from the ... pickpocket and security consultant Apollo Robbins . ... about the Wocket™ biometric smart wallet, a product of NXT-ID, ...
(Date:1/22/2015)... MUNICH , January 22, 2015 ... its tenth year  The European Patent Office to present ... Two British nominations to be featured: Christofer Toumazou ... week featuring former finalists and winners of the Award   ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3
... Reserve researchers have identified a genetic factor that blocks ... attacks, strokes and other potentially life-threatening events. ... latest in a string of discoveries from the laboratory ... a remarkable genetic family. Kruppel-like factors appear to play ...
... Sept. 4, 2013   MedNet Solutions , a global ... systems, is pleased to announce its sponsorship of, participation ... September 10-13 in Chicago .  MedNet ... leading conference...the largest and most prestigious clinical data management ...
... New technology for discovering antibiotics, anti-cancer drugs and other medicines ... treasure hunt that already has given humanity more than 50 ... is the topic of the cover story in Chemical ... Chemical Society. Lisa M. Jarvis, C&EN senior editor, points ...
Cached Biology News:Researchers discover a new pathway in blood vessel inflammation and disease 2MedNet Solutions To Sponsor The SCDM Annual Conference For The Eighth Straight Year 2
Coating : Poly-D-Lysine ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vol working : 2.5-3.0 ml ...
BD BioCoat Laminin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse laminin....
BD BioCoat Collagen I 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of rat tail collagen type I....
... a new product number, created to ... showing no availability yet, please order ... or contact customer service for assistance. ... 148 cm 2 Mfr Desig: ...
Biology Products: